MRK dividend yield: 3.25%. KLAC dividend yield: 4.00%. Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s. KLAC is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in KLAC shares.
Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.
KLAC is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in KLAC shares.
Is MRK or KLAC better for dividend income in 2026?
MRK currently offers a 3.25% yield (3.08/share/year) while KLAC offers 4.00% (2.00/share/year). KLAC provides higher current income. However, MRK has grown its dividend faster (8.2% 5Y CAGR), which may lead to better long-term income through compounding.
How much would $10,000 in MRK vs KLAC earn per year?
With $10,000 invested today: MRK pays approximately $325/year. KLAC pays approximately $400/year. With DRIP reinvestment over 10 years, these grow to $950/year (MRK) and $899/year (KLAC).
Does MRK or KLAC pay monthly dividends?
MRK pays quarterly dividends. KLAC pays quarterly dividends. Neither pay monthly — both use a quarterly schedule, which is preferred by investors who need regular cash flow.
📬
Get this MRK vs KLAC comparison by email
Save your analysis + get weekly dividend insights. Free forever.